Fischer Anne C, Beck Suzanne E, Smith Carolina I, Laube Beth L, Askin Frederic B, Guggino Sandra E, Adams Robert J, Flotte Terence R, Guggino William B
Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Mol Ther. 2003 Dec;8(6):918-26. doi: 10.1016/j.ymthe.2003.08.015.
Bronchoscopic microspraying of recombinant adeno-associated viral (rAAV) vectors targets high doses of vector directly to pulmonary epithelium. Single-dose endobronchial gene therapy trials have been accomplished in cystic fibrosis patients; however, repeated dosing strategies are likely essential for lifetime correction. These studies address whether serial redosing with rAAV2 vectors results in an antiserotypic response and, furthermore, whether it triggers an inflammatory response prohibitive to transgene expression. Serial redosing of 9 x 10(11) infectious units of aerosolized rAAV2 vectors to rhesus macaques resulted in successful gene transfer by quantitative PCR (1.43 x 10(9) copies/g tissue) and transgene expression. Additionally, confocal microscopy and immunohistochemical analysis demonstrated in situ expression localized to the pulmonary epithelium. Although serial redosing did induce a heightened anti-neutralizing antibody response in sera, gene transfer prevailed with resultant expression. This study is the first to demonstrate successful gene transfer subsequent to repeated aerosolized doses of rAAV2 in immunocompetent nonhuman primates without associated inflammatory responses prohibitive to transgene expression.
重组腺相关病毒(rAAV)载体的支气管镜微量喷雾可将高剂量载体直接靶向肺上皮细胞。囊性纤维化患者已完成单剂量支气管内基因治疗试验;然而,重复给药策略可能对终身纠正至关重要。这些研究探讨了用rAAV2载体连续重新给药是否会产生抗血清型反应,此外,它是否会引发抑制转基因表达的炎症反应。对恒河猴连续重新给药9×10¹¹个感染单位的雾化rAAV2载体,通过定量PCR(1.43×10⁹拷贝/克组织)和转基因表达实现了成功的基因转移。此外,共聚焦显微镜和免疫组织化学分析证明原位表达定位于肺上皮细胞。尽管连续重新给药确实在血清中诱导了增强的抗中和抗体反应,但基因转移仍占优势并产生了表达。本研究首次证明,在具有免疫活性的非人灵长类动物中,重复雾化剂量的rAAV2后成功进行了基因转移,且没有出现抑制转基因表达的相关炎症反应。